Case Questions
Case Questions
a. Based on the feasibility analysis work Kaneb had completed as of December 2015,
was her new venture idea an attractive opportunity?
b. What evidence indicated that it was feasible for Kaneb to pursue this potential
opportunity, what evidence suggested the opposite?
c. What were the most critical issues that remained to be addressed as a pre-cursor to
developing a business plan that could be presented to sophisticated investors?
d. What alternative approaches could Kaneb have deployed for dealing with each of
the most critical issues?
e. If you had been in Kaneb’s position and you had decided to continue pursuing your
new venture, which of the alternative approaches for addressing each of the most
critical issues would you have implemented?
f. As you reflect on the dramatic career transition Kaneb was considering, what factors
might have inspired her to decide to launch Parlay, and what concerns might have
given her pause? How does Kaneb’s situation inform your own thinking about a
potential career transition post-MBA?
https://next.canvanizer.com/demo/wA-82vhUOBc
a. What are the advantages and disadvantages of Coquis buying Belle Fleur?
b. How many floral arrangements must Coquis sell to break even at (i) Belle Fleur and
(ii) Floral Filosophy?
c. Should Coquis continue to use Wireflora?
d. Is $ 145,000 a fair price for Belle Fleur? Why or why not?
e. Is there a third option that Coquis should consider?
6. Dr Narendran’s Dilemma (A00010)
a. What is the research and teaching mandate of IMC? How does Dr Narendran view
“research results”?
b. What does Dr Ramkumar want?
c. What is patenting and what are the benefits of intellectual property protection for
IMC?
d. Should IMC file a patent application for the herbo-mineral Siddha cardiovascular
product for coronary atherosclerosis developed by Dr Ramkumar?
a. How did Sanergy’s association with MIT, and access to blue-chip investors (Eleos,
Acumen) benefit the organization during its scaling up phase?
b. Why was access to both grant and equity funding important? How did that inform
Sanergy on how to structure its businesses?
c. In order to successfully launch its sanitation and fertilizer businesses, Sanergy had
to invest in developing its value chain. What are the opportunities and risks that
come with such an approach? Were there any adjacent companies that Sanergy
could have, or still can, partner with?
d. Given Sanergy’s need to invest in building out two separate value chains, what is
Sanergy’s path to financial sustainability and, ultimately, profitability? If
successful, how can Sanergy’s business model be replicated in other markets?